BMEA · Biomea Fusion Inc. Common Stock
View on chartInsiders & Stakes
| Stergiopoulos Sotirios Director | ▲ Buy | Open Market | 4,400,000 Shares held | 9/17/2021 | View profile |
| Bihua Chen Chairperson and CEO | ▲ Buy | Open Market | 3,570,872 Shares held | 3/30/2023 | View profile |
| A2A Pharmaceuticals, Inc. 10% Owner | ▼ Sell | Open Market | 3,500,000 Shares held | 6/1/2023 | View profile |
| Rainer M. Erdtmann President & COO | ▲ Buy | Open Market | 723,027 Shares held | 12/11/2025 | View profile |
| Butler Thomas Andrew CEO | ▲ Buy | Open Market | 228,470 Shares held | 8/23/2021 | View profile |
| Michael J.M. Hitchcock Director | ▲ Buy | Open Market | 115,000 Shares held | 12/2/2025 | View profile |
| Franco Valle Chief Financial Officer | ▲ Buy | Grant | 42,995 Shares held | 11/30/2024 | View profile |
| Juan Pablo Frias Chief Medical Officer | ▲ Buy | Grant | 349 Shares held | 5/31/2024 | View profile |
| Biomea Health, LLC 10% Owner | ▼ Sell | Other | 0 Shares held | 6/1/2022 | View profile |
Transaction History
| Rainer M. Erdtmann | ▲ Buy | Open Market | 30,000 | $43K | 12/11/2025 |
| Michael J.M. Hitchcock | ▲ Buy | Open Market | 100,000 | $99K | 12/2/2025 |
| Rainer M. Erdtmann | ▲ Buy | Open Market | 10,000 | $11K | 12/1/2025 |
| Rainer M. Erdtmann | ▲ Buy | Open Market | 40,000 | $44K | 11/28/2025 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 10,000 | $0 | 1/31/2025 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 10,000 | $0 | 1/31/2025 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 10,000 | $0 | 1/31/2025 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 10,000 | $0 | 1/31/2025 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 10,000 | $0 | 1/31/2025 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 10,000 | $0 | 1/31/2025 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 40,000 | $0 | 1/28/2025 |
| Franco Valle | ▲ Buy | Grant | 495 | $3K | 11/30/2024 |
| Michael J.M. Hitchcock | ▲ Buy | Open Market | 10,000 | $101K | 9/30/2024 |
| Franco Valle | ▲ Buy | Open Market | 12,509 | $55K | 6/11/2024 |
| Franco Valle | ▲ Buy | Grant | 4,448 | $17K | 5/31/2024 |
| Juan Pablo Frias | ▲ Buy | Grant | 349 | $3K | 5/31/2024 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 3,000 | $0 | 12/29/2023 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 3,000 | $0 | 12/29/2023 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 3,000 | $0 | 12/29/2023 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 3,000 | $0 | 12/29/2023 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 3,000 | $0 | 12/29/2023 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 3,000 | $0 | 12/29/2023 |
| Rainer M. Erdtmann | ▼ Sell | Gift | 12,000 | $0 | 12/29/2023 |
| Franco Valle | ▲ Buy | Grant | 1,345 | $5K | 11/30/2023 |
| A2A Pharmaceuticals, Inc. | ▼ Sell | Open Market | 50,000 | $1.7M | 6/1/2023 |
| A2A Pharmaceuticals, Inc. | ▼ Sell | Open Market | 75,000 | $2.5M | 5/31/2023 |
| Franco Valle | ▲ Buy | Grant | 4,273 | $16K | 5/31/2023 |
| A2A Pharmaceuticals, Inc. | ▼ Sell | Open Market | 25,000 | $846K | 5/12/2023 |
| A2A Pharmaceuticals, Inc. | ▼ Sell | Open Market | 150,000 | $5.2M | 5/9/2023 |
| A2A Pharmaceuticals, Inc. | ▼ Sell | Open Market | 100,000 | $3.4M | 5/8/2023 |
| A2A Pharmaceuticals, Inc. | ▼ Sell | Open Market | 200,000 | $5.8M | 4/20/2023 |
| A2A Pharmaceuticals, Inc. | ▼ Sell | Open Market | 200,000 | $6.3M | 3/31/2023 |
| Bihua Chen | ▲ Buy | Open Market | 400,000 | $12.0M | 3/30/2023 |
| Franco Valle | ▲ Buy | Grant | 2,518 | $10K | 11/30/2022 |
| Michael J.M. Hitchcock | ▲ Buy | Open Market | 5,000 | $40K | 11/14/2022 |
| Franco Valle | ▲ Buy | Open Market | 4,100 | $31K | 11/11/2022 |
| A2A Pharmaceuticals, Inc. | ▲ Buy | Open Market | 30,684 | $426K | 8/16/2022 |
| A2A Pharmaceuticals, Inc. | ▼ Sell | Open Market | 34,658 | $389K | 7/21/2022 |
| A2A Pharmaceuticals, Inc. | ▼ Sell | Open Market | 34,658 | $408K | 6/24/2022 |
| Biomea Health, LLC | ▼ Sell | Other | 4,365,342 | $0 | 6/1/2022 |
| Franco Valle | ▲ Buy | Grant | 3,307 | $15K | 5/31/2022 |
| Franco Valle | ▲ Buy | Open Market | 10,000 | $87K | 1/14/2022 |
| A2A Pharmaceuticals, Inc. | ▲ Buy | Open Market | 34,658 | $380K | 9/17/2021 |
| Stergiopoulos Sotirios | ▲ Buy | Open Market | 34,658 | $380K | 9/17/2021 |
| Rainer M. Erdtmann | ▲ Buy | Open Market | 24,000 | $317K | 8/23/2021 |
| Butler Thomas Andrew | ▲ Buy | Open Market | 24,000 | $317K | 8/23/2021 |
| Rainer M. Erdtmann | ▲ Buy | Open Market | 14,000 | $151K | 8/18/2021 |
| Butler Thomas Andrew | ▲ Buy | Open Market | 14,000 | $151K | 8/18/2021 |
| Butler Thomas Andrew | ▲ Buy | Open Market | 14,000 | $151K | 8/17/2021 |
| Rainer M. Erdtmann | ▲ Buy | Open Market | 14,000 | $151K | 8/17/2021 |
| Butler Thomas Andrew | ▲ Buy | Open Market | 176,470 | $3.0M | 4/15/2021 |
| Rainer M. Erdtmann | ▲ Buy | Open Market | 176,470 | $3.0M | 4/15/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Biomea Fusion Cancels Equity Offering, Shares Drop 19%
Biomea Fusion announced the termination of its proposed public equity offering, citing market conditions. The cancellation removes expected dilution relief and leaves the company with near‑term runway pressure. Following the news, the stock fell about 19% in after‑hours trading. The development occurs amid broader health‑care stock activity.
Biomea Fusion Cancels Equity Offering, Shares Drop 19%. Biomea Fusion announced the termination of its proposed public equity offering, citing market conditions. The cancellation removes expected dilution relief and leaves the company with near‑term runway pressure. Following the news, the stock fell about 19% in after‑hours trading. The development occurs amid broader health‑care stock activity.